Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

598-CL-008

NCT ID:

NCT00048659

Start Date:

Completion Date:

June 2004

Related Keywords:

• Hormone-Refractory Prostate Cancer
• Prostatic Neoplasms
• Androgen-independent prostate cancer
• Neoplasms
• Prostatic Neoplasms

Name	Location
Washington University School of Medicine	Saint Louis, Missouri  63110
Henry Ford Hospital	Detroit, Michigan  48202
Virginia Mason Medical Center	Seattle, Washington  98111
Memphis Cancer Center	Memphis, Tennessee  38119
Alaska Clinical Research Center, LLC	Anchorage, Alaska  99508
Western Clinical Research, Inc.	Torrance,, California  90505-4763
San Bernardino Urological Associates	San Bernardino, California
Shands Hospital	Gainesville, Florida
Sylvester Comprehensive Cancer Center	Miami, Florida
Georgia Urology,PA Research Institute	Atlanta, Georgia
University of Illinois, Department of Urology	Chicago, Illinois
University of Chicago, Section of Hematology/Oncology	Chicago, Illinois
Michiana Hematology/Oncology	South Bend, Indiana
The Urologic Institute of New Orleans	Gretna, Louisiana